Tabula Rasa Healthcare Inc. (NASDAQ:TRHC)‘s stock had its “overweight” rating reissued by stock analysts at Piper Jaffray Companies in a report released on Wednesday, The Fly reports. They currently have a $29.00 price target on the stock, up from their previous price target of $20.00. Piper Jaffray Companies’ price target would suggest a potential upside of 13.02% from the stock’s current price.

TRHC has been the topic of several other research reports. Chardan Capital upped their price objective on Tabula Rasa Healthcare from $19.50 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and set a $16.00 price objective on shares of Tabula Rasa Healthcare in a research note on Friday, July 14th. Wells Fargo & Company cut Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $17.00 to $21.00 in a research note on Thursday, September 7th. Robert W. Baird upped their price objective on Tabula Rasa Healthcare from $17.00 to $18.00 and gave the company an “outperform” rating in a research note on Tuesday, August 8th. Finally, UBS AG upped their price objective on Tabula Rasa Healthcare from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, August 30th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $20.71.

Tabula Rasa Healthcare (NASDAQ TRHC) traded down 1.46% on Wednesday, hitting $25.66. The stock had a trading volume of 110,499 shares. Tabula Rasa Healthcare has a 12-month low of $10.39 and a 12-month high of $26.79. The firm’s market cap is $443.56 million. The company’s 50 day moving average is $23.99 and its 200 day moving average is $23.99.

Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its quarterly earnings data on Monday, August 7th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.06. Tabula Rasa Healthcare had a negative return on equity of 9.58% and a negative net margin of 10.27%. The firm had revenue of $29.70 million for the quarter, compared to analysts’ expectations of $27.84 million. The company’s revenue was up 32.6% compared to the same quarter last year. On average, equities research analysts expect that Tabula Rasa Healthcare will post $0.39 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Piper Jaffray Companies Reiterates Overweight Rating for Tabula Rasa Healthcare Inc. (TRHC)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/20/piper-jaffray-companies-reiterates-overweight-rating-for-tabula-rasa-healthcare-inc-trhc.html.

In other news, insider Orsula V. Knowlton sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $22.10, for a total transaction of $176,800.00. Following the completion of the transaction, the insider now directly owns 887,407 shares of the company’s stock, valued at $19,611,694.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 24,000 shares of company stock valued at $428,080 over the last ninety days. Corporate insiders own 45.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Hood River Capital Management LLC grew its holdings in Tabula Rasa Healthcare by 7.5% in the 2nd quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock worth $12,420,000 after buying an additional 57,724 shares in the last quarter. Wellington Management Group LLP grew its holdings in Tabula Rasa Healthcare by 37.2% in the 1st quarter. Wellington Management Group LLP now owns 782,142 shares of the company’s stock worth $10,544,000 after buying an additional 212,164 shares in the last quarter. Vanguard Group Inc. grew its holdings in Tabula Rasa Healthcare by 13.4% in the 2nd quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock worth $3,566,000 after buying an additional 27,997 shares in the last quarter. Boston Partners grew its holdings in Tabula Rasa Healthcare by 17.1% in the 2nd quarter. Boston Partners now owns 235,180 shares of the company’s stock worth $3,540,000 after buying an additional 34,360 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Tabula Rasa Healthcare by 97.4% in the 2nd quarter. Northern Trust Corp now owns 95,862 shares of the company’s stock worth $1,443,000 after buying an additional 47,306 shares in the last quarter. 28.85% of the stock is owned by institutional investors and hedge funds.

About Tabula Rasa Healthcare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

The Fly

Analyst Recommendations for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.